

**IN THE CLAIMS:**

A clean set of claims following entry of the present amendment is attached hereto as Appendix A.

Please amend the claims as follows:

Sub A  
B3

8. (Amended) The method of claim 7 wherein the antagonist [further] comprises:  
(a) an Fc polypeptide, [or] leucine zipper domain, peptide linker; and  
(b) about two to four polypeptides comprising a TWEAK receptor extracellular domain or fragments or variants thereof that are capable of binding TWEAK.

A2

28. (Amended) An antagonist comprising:  
(a) an Fc polypeptide, [or] leucine zipper domain, or peptide linker; and  
(b) a TWEAK receptor extracellular domain or fragment or variant thereof that is capable of binding TWEAK.

A3

36. (Amended) The method of claim 35 further comprising determining the ability of the test compound to modulate endothelial cell proliferation, [and/or] endothelial cell migration, and/or angiogenesis.

A4

38. (Amended) The method of [caim] claim 35 wherein the modulation is inhibitory.

Sub C1

39. (Amended) A method of modulating the binding of TWEAK to the TWEAK receptor in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a composition comprising a TWEAK receptor antagonist selected from the group consisting of : (a) a polypeptide comprising a soluble TWEAK receptor extracellular domain; and (b) an antibody that binds to the TWEAK receptor extracellular domain.